Grace Therapeutics, Inc. (GRCE) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2026, Grace Therapeutics reported revenue of $0. Net income was -$7.8M, or -$0.47 per diluted share. Operating activities generated -$8.9M of cash. At fiscal year end, Grace Therapeutics held $66.7M in total assets against $2.8M in total liabilities, including $17.0M of cash and equivalents.
Open the full interactive Grace Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Grace Therapeutics Key Stats
| Share Price | $1.99 |
|---|---|
| Market Cap | $34.4M |
| 52-Week Range | $1.99 – $5.13 |
| Shares Outstanding | 17.3 million (basic, 2027 Q1) |
Grace Therapeutics Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Revenue | $196,000 | $0 | $0 | $0 | $0 | $0 |
| Cost of Goods Sold | $76,000 | $0 | — | — | — | — |
| Gross Profit | $120,000 | $0 | — | — | — | — |
| Operating Income | -$16.4M | -$15.6M | -$52.2M | -$12.9M | -$16.7M | -$11.1M |
| Pre-Tax Income | -$19.7M | -$10.5M | -$52.0M | -$14.7M | -$12.8M | -$9.5M |
| Income Tax | — | -$648,000 | -$9.5M | -$1.8M | -$3.2M | -$1.7M |
| Net Income | -$19.7M | -$9.8M | -$42.4M | -$12.9M | -$9.6M | -$7.8M |
| Diluted EPS | -$8.16 | -$1.62 | -$5.70 | -$1.35 | -$0.79 | -$0.47 |
Grace Therapeutics Quarterly Results
| 2026 Q2 | 2026 Q3 | 2026 Q4 | 2027 Q1 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$938,000 | -$2.3M | -$1.2M | -$15.8M |
| Diluted EPS | -$0.06 | -$0.14 | -$0.07 | -$0.91 |
Grace Therapeutics Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $50.9M | $30.3M | $27.9M | $23.0M | $22.1M | $17.0M |
| Current Assets | $62.4M | $45.5M | $29.3M | $24.0M | $22.7M | $17.4M |
| Total Assets | $62.5M | $128.6M | $79.1M | $73.3M | $72.0M | $66.7M |
| Current Liabilities | $1.6M | $3.3M | $3.4M | $1.7M | $1.9M | $2.1M |
| Total Liabilities | $6.8M | $20.4M | $11.2M | $11.6M | $5.4M | $2.8M |
| Shareholders' Equity | $55.7M | $108.3M | $68.0M | $61.7M | $66.6M | $63.9M |
Grace Therapeutics Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$14.3M | -$17.2M | -$15.9M | -$12.3M | -$14.9M | -$8.9M |
| Cash From Investing | -$9.9M | -$3.5M | $13.2M | $104,000 | $0 | $0 |
| Cash From Financing | $59.5M | $0 | $304,000 | $7.4M | $14.0M | $3.7M |
Figures from Grace Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Grace Therapeutics financials page for every line item.
Grace Therapeutics Company Profile
| Ticker | GRCE |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Princeton, New Jersey |
| Incorporated in | Delaware |
| Fiscal Year End | March 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001444192 |
Frequently Asked Questions
What was Grace Therapeutics' revenue in fiscal 2026?
Grace Therapeutics (GRCE) reported revenue of $0 for fiscal 2026.
What is Grace Therapeutics' annual revenue history?
Grace Therapeutics' annual revenue by fiscal year: 2021: $196,000; 2022: $0; 2023: $0; 2024: $0; 2025: $0; 2026: $0.
What was Grace Therapeutics' net income in fiscal 2026?
Grace Therapeutics reported net income of -$7.8M for fiscal 2026.
What was Grace Therapeutics' earnings per share (EPS) in fiscal 2026?
Grace Therapeutics' diluted EPS was -$0.47 for fiscal 2026 (adjusted for any later stock splits).
What was Grace Therapeutics' revenue last quarter?
In its most recent reported quarter (2027 Q1), Grace Therapeutics reported revenue of $0.
How many shares of Grace Therapeutics are outstanding?
Grace Therapeutics reported a weighted average of 17.3 million basic shares outstanding in 2027 Q1.
What is Grace Therapeutics' market cap?
Based on its latest closing price, Grace Therapeutics (GRCE) has a market capitalization of about $34.4M.
When does Grace Therapeutics' fiscal year end?
Grace Therapeutics' fiscal year end, as registered with the SEC, is March 31.
Where is Grace Therapeutics headquartered?
Grace Therapeutics lists its business address in Princeton, New Jersey in its SEC filings.